Retatrutide 5mg
Triple agonist (GIP/GLP-1/glucagon) — starter vial for early titration phases.
Wks 1–2 @ 1 mg, wks 3–4 @ 2 mg, wks 5–8 @ 4 mg (early titration)
Key Benefits
simultaneously targets GIP, GLP-1, and glucagon receptors for synergistic metabolic effects no single agonist can match
Phase 2 trials showed 24.2% body weight loss at 48 weeks, the highest ever recorded for an injectable agent
addresses insulin resistance, dyslipidemia, and visceral fat accumulation through three complementary mechanisms
liver fat reduced by 81.7% from baseline in subgroup analysis, making it the most potent compound for fatty liver research
Recommended Injection Sites
Optimal injection locations for Retatrutide 5mg based on its route (Subcutaneous injection) and pharmacokinetic profile.
Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.
Tap a zone to inject
Preferred site for early titration doses. Consistent absorption; easy to self-administer weekly.
Reliable rotation site. Slightly slower Cmax but equivalent weekly AUC for low titration doses.
Third rotation site for weekly protocol. Requires assistance.
Rotate weekly between abdomen, thigh, and upper arm. Consistent rotation prevents site reactions during the multi-week titration protocol.
- IV administration
- Intramuscular injection
- Scar tissue or lipodystrophic areas
Active Signaling Pathway
The 5mg starter vial is designed for the initial titration phase (weeks 1–8), allowing the body to adapt to triple receptor agonism before escalating to higher doses.
Recommended Stacks
Retatrutide 5mg is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
Retatrutide Advanced Protocol
The most potent metabolic research stack available — triple receptor agonism with full titration support.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 5mg vial — and when to plan your next order.
Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.
Scientific Background
Mechanism of Action
Retatrutide (LY3437943) is a single peptide molecule engineered to simultaneously agonize three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. The glucagon component drives hepatic fat oxidation and energy expenditure — a mechanism absent in dual GIP/GLP-1 agonists — making it uniquely potent for metabolic research.
Clinical Context
Retatrutide represents the leading edge of incretin-based obesity pharmacology. Its triple mechanism addresses the three key drivers of metabolic disease: insulin resistance (GIP), appetite/satiety (GLP-1), and energy expenditure (glucagon). The 5mg starter vial is designed for the critical early titration phase where GI tolerance is established.
Research Highlights
- Phase 2 NEJM 2023 trial: 24.2% mean body weight reduction at 48 weeks (12 mg/week dose) — highest ever reported for an injectable agent
- Glucagon receptor agonism increases energy expenditure by ~15% above baseline, complementing appetite suppression
- Demonstrated significant reductions in liver fat (NAFLD) and visceral adipose tissue beyond weight loss alone
- 5mg vial covers weeks 1–8 of standard titration (1–4 mg/week) before escalating to higher maintenance doses
Storage & Reconstitution
Ideal for the first 4–8 weeks of titration (1–2 mg/week). Pair with the 10mg vial for continued escalation.